LBRX (STOCKS)
LB Pharmaceuticals Inc Common Stock
$28.500000
+0.080000 (+0.28%)
Prev close: $28.420000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Heather D. Turner
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $817.28M
- Employees
- 27
- P/E (TTM)
- -19.18
- P/B (TTM)
- 2.15
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.67 | $-0.76 | +0.0899 | +11.83% |
|
Dec 2025 (Q4)
|
$-0.45 | $-0.46 | +0.0065 | +1.42% |
|
Sep 2025 (Q3)
|
$-0.61 | $-0.46 | -0.1459 | -31.44% |
Financial Statements
| Nonoperating Income/Loss | $7.13M |
| Operating Expenses | $46.08M |
| Research and Development | $27.97M |
| Other Operating Expenses | $17.81M |
| Income/Loss From Continuing Operations After Tax | -$38.95M |
| Income/Loss From Continuing Operations Before Tax | -$38.95M |
| Income Tax Expense/Benefit | $1.00K |
| Net Income/Loss | -$38.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$38.95M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.77M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$25.18M |
| Preferred Stock Dividends And Other Adjustments | -$25.18M |
| Basic Earnings Per Share | $10.99 |
| Diluted Earnings Per Share | $10.99 |
| Basic Average Shares | 35,928,069 |
| Diluted Average Shares | 35,928,069 |
| Assets | $393.48M |
| Current Assets | $389.07M |
| Cash | $364.85M |
| Other Current Assets | $24.22M |
| Noncurrent Assets | $4.41M |
| Fixed Assets | $1.53M |
| Other Non-current Assets | $2.88M |
| Liabilities | $14.79M |
| Current Liabilities | $10.91M |
| Accounts Payable | $7.12M |
| Other Current Liabilities | $3.79M |
| Noncurrent Liabilities | $3.88M |
| Equity | $378.69M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $378.69M |
| Liabilities And Equity | $393.48M |
| Net Cash Flow From Operating Activities | -$50.37M |
| Net Cash Flow From Operating Activities, Continuing | -$50.37M |
| Net Cash Flow From Investing Activities | -$44.90M |
| Net Cash Flow From Investing Activities, Continuing | -$44.90M |
| Net Cash Flow From Financing Activities | $393.25M |
| Net Cash Flow From Financing Activities, Continuing | $393.25M |
| Net Cash Flow | $297.98M |
| Net Cash Flow, Continuing | $297.98M |
| Comprehensive Income/Loss | -$38.74M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$38.74M |
| Other Comprehensive Income/Loss | -$33.87M |